Literature DB >> 13554011

Cortisone and its analogues in the nephrotic syndrome.

G A SMART.   

Abstract

Entities:  

Keywords:  CORTISONE/therapeutic use; NEPHROTIC SYNDROME/therapy

Mesh:

Substances:

Year:  1958        PMID: 13554011      PMCID: PMC2501392          DOI: 10.1136/pgmj.34.392.325

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


× No keyword cloud information.
  8 in total

1.  Continuous therapy of nephrotic syndrome in children with corticotropin gel.

Authors:  A J MERRILL; J WILSON; L F TIMERLAKE
Journal:  AMA Arch Intern Med       Date:  1954-12

2.  The clinical value of renal biopsy.

Authors:  R M KARK; R C MUEHRCKE; C L PIRANI; V E POLLAK
Journal:  Ann Intern Med       Date:  1955-10       Impact factor: 25.391

3.  [The interrupted prolonged treatment of the nephrotic syndrome in the child with ACTH and cortisone].

Authors:  R DEBRE; P ROYER; B LEVEQUE; Z MINOR
Journal:  Sem Hop       Date:  1956-01-22

4.  Renal functions in the course of the nephrotic syndrome in children.

Authors:  E BRUCK; M RAPOPORT; M I RUBIN
Journal:  J Clin Invest       Date:  1954-04       Impact factor: 14.808

5.  The nephrotic syndrome. I. Histological changes illustrated by means of biopsy of the kidney.

Authors:  M BJØRNEBOE; C BRUN; H GORMSEN; P IVERSEN; F RAASCHOU
Journal:  Acta Med Scand Suppl       Date:  1952

6.  Serum lipid analysis in the nephrotic syndrome under ACTH administration.

Authors:  J W SOSHEA; E B FARNSWORTH
Journal:  J Lab Clin Med       Date:  1951-09

7.  Changes in serum complement during the course and treatment of glomerulonephritis.

Authors:  K LANGE; F GRAIG; J OBERMAN; L SLOBODY; G OGUR; F LoCASTO
Journal:  AMA Arch Intern Med       Date:  1951-10

8.  [Prognosis of the nephrosis syndrome].

Authors:  G FANCONI; C KOUSMINE; W FRISCH KNECHT
Journal:  Helv Paediatr Acta       Date:  1951-06
  8 in total
  1 in total

1.  Diuretics: a review.

Authors:  H G LLOYD-THOMAS
Journal:  Postgrad Med J       Date:  1959-11       Impact factor: 2.401

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.